Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer

Solé, L.A.; Albanell, Joan; Bellmunt, Joaquim; Ribas, A.; Gallego, Óscar; Carulla, Joan

doi:10.1002/1097-0142(19950201)75:3<831::aid-cncr2820750314>3.0.co;2-s

Cited by 14 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early reports of oral tegafur with or without leucovorin modulation in breast cancer revealed encouraging response rates [198][199][200][201][202]. UFT has been tested as salvage therapy in breast cancer patients [203].…”

Section: Uracil-tegafurmentioning

confidence: 99%

Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents

Vogel

Nabholtz

1999

The Oncologist

View full text Add to dashboard Cite

Key Words. Breast neoplasms · Docetaxel · Paclitaxel · Vinorelbine · Review ABSTRACT Purpose. New agents for the palliative treatment of metastatic breast cancer have emerged in the 1990s. This review summarizes the response rates of these agents with an emphasis on recent findings, such as presentations from the 1998 Meeting of the American Society of Clinical Oncology. Methods. The English medical literature was reviewed to identify clinical trials involving monotherapy for the treatment of metastatic breast cancer. Three agents-paclitaxel, vinorelbine, and docetaxel-are emphasized because their databases are extensive enough to allow interesting comparisons. Liposomal-encapsulated anthracyclines, losoxantrone, gemcitabine, oral surrogates of continuous-infusion fluorouracil, raltitrexed, LY 231514, edatrexate, topoisomerase I inhibitors, and trastuzumab are reviewed briefly.Results. Many of the new agents produce response rates approaching or even surpassing those achievable with doxorubicin monotherapy. Compared with older agents, some new agents have improved or at least different safety profiles, and some are easier to administer.Discussion and conclusions. The new agents offer useful therapeutic options that make them suitable for combining with each other and with older agents, which could result in more effective regimens for metastatic disease, and, ultimately, primary disease in the adjuvant setting. The chemotherapeutic paradigms governing the management of breast cancer for the past three decades are likely to change as we move into the 21st century.

show abstract

Section: Uracil-tegafurmentioning

confidence: 99%

Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents

Vogel

Nabholtz

1999

The Oncologist

View full text Add to dashboard Cite

show abstract

“…FT, with and without leucovorin, has been explored as an oral, less‐toxic alternative to 5‐FU. In a phase 2 study of patients with previously treated metastatic breast cancer, 25 patients received 750 mg/m 2 /day of FT with 45 mg/day of leucovorin for 21 days, repeated every 28 days 16. An overall response rate of 32% was observed, and 48% of patients experienced disease stabilization (median duration, 6 months).…”

mentioning

confidence: 99%

A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice‐daily regimen to treat patients with recurrent metastatic breast cancer

Hortobágyi¹,

Young²,

Karwal³

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: UFT, a combination of uracil and ftorafur, was developed to combine the cytotoxic effects of 5-fluorouracil (5-FU) with convenient oral dosing. Leucovorin is combined with UFT to further potentiate the effect of 5-FU on tumor cells. Orally administered UFT and leucovorin provide higher peak plasma concentrations of 5-FU and prolonged therapeutic 5-FU concentrations compared with continuous infusion of 5-FU. METHODS: Ninety-four patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle. The total daily dose of UFT was 300 mg/m 2 ,

show abstract

Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma

Ribas

Albanell

Solé‐Calvo

et al. 1998

Cancer

Self Cite

View full text Add to dashboard Cite

RESULTS.Forty-seven patients were included, 44 of whom were fully assessable.bron Barcelona, Spain.Three patients (7%) achieved a complete remission and 17 (38.6%) achieved a partial remission, for an objective response rate of 45.5% (95% confidence interval, 29-59%). The median duration of response was 11 months. In previously untreated patients the response rate was 54.5%. In patients previously treated with anthracycline or 5-fluorouracil-based regimens the response rates were 41% and 39%, respectively. Sixteen patients (36.4%) had disease stabilization. The median overall time to progression was 10 months. Toxicities usually were mild and were comprised of leukocytopenia, mucositis, emesis, and diarrhea. CONCLUSIONS. Chronic oral tegafur and folinic acid combined with intravenouscyclophosphamide and methotrexate at the dose and schedule used in the current study has significant antitumor activity both as first-line chemotherapy as well as in other patients with advanced breast carcinoma who had prior chemotherapy.This regimen is well tolerated, with gastrointestinal toxicity being the most frequent Presented in part at the 25th meeting of the and dose-limiting toxicity.

show abstract

Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer

Cited by 14 publications

References 21 publications

Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents

Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents

A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice‐daily regimen to treat patients with recurrent metastatic breast cancer

Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma

Contact Info

Product

Resources

About